All-trans retinoic acid (ATRA) induces differentiation of acute t(5;17)(q32;q12).
Bone marrow cells were obtained at second relapse, a time when the marrow showed greater than 80% blasts and promyelocytes with t(5;17). The mononuclear fraction was obtained by Ficoll-Hypaque centrifugation. Cells were plated in IMDM Introduction (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum (Paragon, Baltimore, MD, USA), glutamine, genAll-trans retinoic acid (ATRA) induces transient complete tamicin, and either 10 −6 M ATRA (Sigma, St Louis, MO, USA) remissions in over 90% of patients with acute promyelocytic or ethanol (vehicle control) at 37°C and 5% CO 2 . leukemia (APL). 1, 2 This action of ATRA reflects its ability to induce differentiation of APL leukemic blasts.
In vitro exposure of APL blasts to micromolar concen-
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trations of ATRA similarly results in synchronous differentiation of the leukemic cells. 1, 3, 4 The ability to differentiate in After 7 days of culture, cytospins of cells were air dried and response to ATRA is unique to APL. The molecular mechGiemsa stained using standard protocols. Manual differentials anism underlying this phenomenon remains obscure. Many were performed. Induction of NADPH oxidase activity (a researchers have focused their investigations on the gene promarker of phagocytic differentiation) was assessed by ducts that result from the reciprocal t(15;17) chromosomal NitroBlue Tetrazolium (NBT) assay. 12 translocation that characterizes the majority of cases of APL. This chromosomal rearrangement juxtaposes the PML gene and the retinoic acid receptor alpha (RARA) gene, leading to Results and discussion expression of PML-RAR and RAR-PML fusion proteins. 5, 6 Rare patients manifest the APL phenotype but with a differCulture of the t(5;17) blasts for 7 days with 10 −6 M retinoic ent genotype. Chen et al 7, 8 have described a variant of APL acid induced a striking morphologic change ( Figure 1 ). that is characterized by t(11;17)(q23; q21). t(11;17) leukemic Whereas the control ethanol-treated culture was characterized cells do not express PML-RAR, but rather a fusion protein by a predominance of cells with round nuclei and perinuclear derived from the PLZF gene and RARA. Blasts from these clear areas indicative of blasts and promyelocytes, most of the patients fail to differentiate in vitro when cultured with reticells treated with retinoic acid developed convoluted and segnoic acid. The t(11;17) patients themselves respond poorly to mented nuclei. Manual differential of Giemsa-stained cytodifferentiation therapy. This observation has led some investispins of the cultured cells indicated maturation of the retinoic gators to propose that expression of the PML-RAR protein is acid-treated population along the granulocytic lineage requisite for response to retinoic acid. 9, 10 ( Table 1 ). There was a concomitant rise in the proportion of We have previously described a second variant of APL with NBT positive cells ( Figure 2 other hand, are curiously non-responsive to retinoic acid, when she had a minimal leukemic burden. We suspect that the clearing of the abnormal cells from the bone marrow was caused by retinoic acid-induced differentiation of the leukemic blasts. The rise in blast count at the end of the trial and the rapid relapse after suspending retinoic acid therapy could be attributed to a rapid onset of retinoic acid refractoriness, as has also been seen in t(15;17) APL. 1 The in vitro sensitivity of the t(5;17) blasts harvested months later is analogous to the observation that t(15;17) blasts remain sensitive to the differentiating effect of retinoic acid in vitro after patients cease to respond in vivo. treated with Ara-C and daunarubicin together with ATRA 45 mg/m 2 /day. On day 4 of the regimen ATRA was discon- Table 1 Differential count tinued because of toxicity. A bone marrow examination on day 13 showed no evidence for leukemic cell differentiation.
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Though the patient did not respond to the 4-day course of ATRA, it is difficult to say whether such a short course was response to retinoic acid. Based on our in vitro data, we suggest that patients with t(5;17) and other non-PLZF-RAR APL and the same C-terminal elements of RARA as in PML-RAR and PLZF-RAR. 13 All three fusion proteins act as retinoic acidvariants be given a therapeutic trial of retinoic acid. dependent transcriptional activators of retinoic acid responsive genes. 5, 6, [13] [14] [15] All three have dominant negative activity on transcriptional activation by wild-type RARA 5, 6, 15 (and RL
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Redner, unpublished observations). The reason for the different phenotype of the t(11;17) variant is unclear, but may relate Because of the limited number of leukemic cells obtained from the patient, no retinoic acid dose response curve was to expression of the RAR-PLZF reciprocal translocation product. 8 attempted. Similarly, insufficient material was obtained to study effects of retinoic acid on expression of NPM-RAR proThe clinical response of our patient to retinoic acid was difficult to gauge. The patient received retinoic acid at a time tein. Immunolocalization studies are currently in progress.
